These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10817688)

  • 21. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
    Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
    Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage-nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolates.
    Blumberg HM; Rimland D; Kiehlbauch JA; Terry PM; Wachsmuth IK
    J Clin Microbiol; 1992 Feb; 30(2):362-9. PubMed ID: 1371517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agr-independent regulation of fibronectin-binding protein(s) by the regulatory locus sar in Staphylococcus aureus.
    Wolz C; Pöhlmann-Dietze P; Steinhuber A; Chien YT; Manna A; van Wamel W; Cheung A
    Mol Microbiol; 2000 Apr; 36(1):230-43. PubMed ID: 10760180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.
    Evans ME; Titlow WB
    J Antimicrob Chemother; 1998 Feb; 41(2):285-8. PubMed ID: 9533474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
    Entenza JM; Marchetti O; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
    Tankovic J; Duval J; Courvalin P
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):35-9. PubMed ID: 7920462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of sub-inhibitory antibiotics on fibronectin-mediated host cell adhesion and invasion by Staphylococcus aureus.
    Rasigade JP; Moulay A; Lhoste Y; Tristan A; Bes M; Vandenesch F; Etienne J; Lina G; Laurent F; Dumitrescu O
    BMC Microbiol; 2011 Dec; 11():263. PubMed ID: 22168812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
    Zhao X; Eisner W; Perl-Rosenthal N; Kreiswirth B; Drlica K
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1023-7. PubMed ID: 12604537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.